Nonalcoholic Steatohepatitis (NASH) Research
Nonalcoholic steatohepatitis (NASH) is fast becoming the leading cause of liver failure today. As the worldwide prevalence of obesity and type 2 diabetes (T2D) increases, so do the complications of NASH.
Menu
We're ready when you are.
We are a leading, global contract research organization. Our team of more than 4,300 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.
We’re ready when you are.
From study design through product launch and beyond, Chiltern is the only resource you need. Our development teams have conducted thousands of clinical trials for a wide range of drugs, biologics, medical devices and diagnostics across all phases of development, involving different study populations and across many therapeutic areas.
